Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

105.78 +0.91 (+0.87%)
Streaming Delayed Price Updated: 12:57 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029). 
Via SBWire
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
Water for Injection Market Trends Outlook Demand 2023 -2030
Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International... 
Via SBWire
This High-Yielding Blue Chip Stock Is a Strong Buy
This big pharma company pays a market-topping dividend to shareholders. 
Via The Motley Fool
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Via Benzinga
A Preview Of Novartis's Earnings
Via Benzinga
Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
Enterprise software maker Snowflake notched a three-month gain of 28.85%, far outpacing the S&P 500’s return of 9.32%. Analysts expect the price to rise 19%. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Death
Exposures Death
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
Exposures COVID-19
Shigella Vaccines Market: Study Navigating the Future Growth Outlook
Get Shigella Vaccines Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third. 
Via Investor's Business Daily
Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium
SAN DIEGO, February 1, 2023 (Newswire.com) - On Feb. 26, 2022, Rancho Biosciences, a leading data sciences services company, launched its Single Cell Data Science (SCDS) pre-competitive consortium,... 
Via Newswire.com
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading: 
Via Benzinga
Envision Pharma Group Hires Leading Industry Executives Dominic Marasco and Gregory Carpenter to Lead Further Expansion of the Business and Support Growing Customer Demand
PHILADELPHIA, January 31, 2023 (Newswire.com) - Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A,... 
Via Newswire.com
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall... 
Via Benzinga
Earnings Scheduled For February 1, 2023
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion. 
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.